Company News »

CRLX101 Selected for Oral Presentation at 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer

Business Wire
Share on StockTwits
Published on

Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting, announced today that preclinical data for CRLX101 as monotherapy and in combination with Avastin(R) have been selected to be the subject of an oral presentation at the 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer to be held February 19-21, 2015 in San Diego, California.

Elizabeth Pham, Ph.D., Postdoctoral Fellow, Sunnybrook Research Institute in Toronto, will discuss the results of preclinical mouse models of advanced metastatic cancer in an abstract presentation titled Translational evaluation of the investigational nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian and breast cancer, as part of a session on biomarkers on Friday, February 20, 1:25 p.m. PT. The ovarian data were the subject of a manuscript published in Clinical Cancer Research.

In an ovarian cancer model, CRLX101 monotherapy was highly efficacious, and chronic low-dose CRLX101 with Avastin reduced HIF-1 up-regulation and resulted in synergistic efficacy, with minimal toxicity in mice. In breast cancer models in mice, CRLX101 monotherapy was highly efficacious, and CRLX101 with Avastin resulted in dramatic, durable primary tumor shrinkages and greatly improved survival.

These data support a growing view in the anti-angiogenesis community that adding a durable HIF-inhibitor like CRLX101 to VEGF inhibitors, which drive up HIF, could lead to important benefits for patients, said Elizabeth Pham, Ph.D.

Elizabeth Pham is a Postdoctoral Fellow in the lab of Robert S. Kerbel, Ph.D., Sunnybrook Research Institute, who serves as a Chair and on the selection committee for the Symposium on Anti-Angiogenesis and Immune Therapies for Cancer. Dr. Kerbel recused himself from the scoring for this abstract due to his affiliation with the research.

About CRLX101

CRLX101 is a dynamically tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and hypoxia-inducible factor-1 (HIF-1), which research suggests is a master regulator of cancer cell survival mechanisms thought to promote drug and radiation resistance. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 250 patients.

About CRLX301

CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. CRLX301 is currently in Phase 1 clinical development.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the bodys normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit

About Ceruleans Dynamic Tumor Targeting Platform

Ceruleans Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the leaky vasculature present in tumors but are too large to pass through the wall of healthy blood vessels. Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about our estimated research and development expenses and sufficiency of cash to fund specified use of cash and other statements containing the words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Avastin(R) is a trademark of Genentech Inc.

Share on StockTwits